In Vitro Activity of a Novel Quinolone, UB-8902, Against Ofloxacin-Resistant Mycobacterium tuberculosis Isolates

• Published in: Microbial drug resistance (Larchmont, N.Y.)
• Main Authors: Tudó, Griselda, Lopez-Gavin, Alexandre, Portell-Buj, Elena, Freixes, Joan, Vila, Jordi, Roman, Angely, Monté, Maria Rosa, Gonzalez-Martin, Julian
• Format: Journal Article
• Language: English
• Published: United States 01.09.2020
• Subjects: in vitro susceptibility; fluoroquinolones; Mycobacterium tuberculosis; UB-8902
• ISSN: 1931-8448
• DOI: 10.1089/mdr.2019.0367

The main objective of this study was to compare activities of a novel fluoroquinolone (FQ), UB-8902, with ofloxacin (OFX), levofloxacin (LFX), and moxifloxacin (MOX) against isolates. Eleven OFX-resistant and 11 drug-susceptible clinical isolates were studied. Individual minimum inhibitory concentrations of OFX, LFX, MOX, and UB-8902 were determined using Middlebrook 7H11 agar. The concentrations studied ranged from 0.125 to 128 μg/mL in twofold dilutions. UB-8902 was more active than LFX and similar to MOX for OFX-resistant isolates. In addition, UB-8902 and MOX showed equal activity against drug-susceptible isolates, both being more active than OFX and LFX. In conclusion, the new FQ, UB-8902, showed good activity against OFX-resistant isolates. Moreover, it showed better activity than OFX and LFX and was equivalent to MOX against FQ-susceptible clinical isolates. UB-8902 can be considered as a drug with potential antituberculous activity, similar to MOX.